ClinicalTrials.gg
Drug

Gadoquatrane clinical trials

Also written BAY1747846.

studies test it
7
open now
0
in phase 3
3
first study started
2019

How each study uses gadoquatrane is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
12 Jun 2026 · AMBELVIST · NDA 219627 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Gadoquatrane (BAY1747846)
4

Development codes

BAY1747846
2

Studies by the year they started

7 studies that test it; most in 2023 (3)

Studies that test gadoquatrane, by start year
YearStudies
20191
20202
20211
20233

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
1
Phase 3
3

Who runs them

Industry 7 · Other 0

Bayer (7)

Studies

Open first, then newest update. How each study uses gadoquatrane is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Codes

What other systems call gadoquatrane · ClinicalTrials.gg INT017515

  • UNII (FDA) OZG7J613HKGADOQUATRANEOne source FDA
  • NCI Thesaurus C184920GadoquatraneOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.